Details for Patent: 10,493,051

Which drugs does patent 10,493,051 protect, and when does it expire?

Patent 10,493,051 protects NOURESS and is included in one NDA.

This patent has one patent family member in one country.

Summary for Patent: 10,493,051

Patent landscape, scope, and claims:

Title:	Cysteine composition and injection
Abstract:	Cysteine compositions comprising less than about 400 .mu.g/L of aluminum. For example, solutions of cysteine comprising a pharmaceutically acceptable solvent, cysteine, and less than about 145 .mu.g/L of aluminum, wherein the solution is devoid of visible particulate matter. Cysteine compositions described herein may be suitable for injection. For example, disclosed cysteine solutions may be provided intravenously to meet amino acid nutritional requirement in individuals receiving total parenteral nutrition. Also provided are processes for preparing cysteine compositions, and methods for providing cysteine to individuals in need thereof.
Inventor(s):	Sutterer; Angela (Chesterfield, MO), Simpson; Jill (Chesterfield, MO), Pouliquen; Gauthier (Ternay, FR), Constancis; Alain (Lyons, FR), Danner; Pierre (Francheville, FR)
Assignee:	Flamel Ireland Limited (Dublin, IE)
Application Number:	16/355,028
Patent Claim Types: see list of patent claims	Formulation;

Drugs Protected by US Patent 10,493,051

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Baxter Hlthcare Corp	NOURESS	cysteine hydrochloride	SOLUTION;INTRAVENOUS	212535-001	Dec 13, 2019		DISCN	Yes	No			Y

International Family Members for US Patent 10,493,051

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	3070798